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In the TAVR (transcatheter aortic valve replacement) ra, trans-apical valve-in-valve mitral 
valve implantation (TA-MVI) is considered an alternative treatment for high risk patients with degenerat d 
mitral bioprosthesis. We report an unusual strategy o remedy to a potentially fatal complication as the mitral 
prosthesis migration into the aortic arch. The dislocated prosthesis was successfully stabilized in the aortic 



































During the last decade the development and the improvement of transcatheter valve procedures allowed th  
treatment also of degenerated bioprosthesis, in mitral position, especially in high risk patients [1]. Despite 
the excellent results reported, potentially fatal complications are still present. In this report we describe a 
case of mitral prosthesis dislocation and migration into the aortic arch, and the strategy that have been used 
to remedy.  
 
An 85-year-old male patient (BSA 1.82 mq) presented with a worsening of exertional dyspnoea (NYHA 
functional class III).  In 2004 he underwent to mitral valve replacement for severe mitral regurgitation with a 
31-mm Hancock bioprosthesis and a concomitant coronary artery by-pass grafting (CABG). Co morbidity 
conditions included a chronic obstructive pulmonary disease, previous major stroke (2013), episodes of 
digestive hemorrhage due to esophageal varicies, chronic gastritis, abdominal aortic aneurysm and chronic 
atrial fibrillation. In the last month the patient was admitted in our hospital for heart failure, with evidence of 
mitral bioprosthetic dysfunction. The echocardiography confirmed the severe bioprosthetic mitral 
regurgitation with elevated pulmonary artery systolic pressure 55 mmHg, moderate aortic valve regurgitation 
and a left ventricle (LV) ejection fraction of 61%. Preoperative coronary angiography evidenced good 
patency of previous by-pass. The patient was evaluated by our “heart team” and considering to be high-r sk 
for a conventional mitral valve replacement (European system for cardiac operative risk evaluation stadard 
18, logistic 78%) and a transcatheter valve procedure was preferred. The procedure was performed in the 
hybrid operating room by our cardiovascular team (cardiac surgeons, interventional cardiologists and car iac 
anesthesiologist). A left anterior thoracotomy was performed through the fifth intercostal space and 
transapical access through the pericardial was created. The ventricular apex was punctured with a guidew re, 
which was advanced through the opening of the mitral prosthesis into the left atrium. Transesophageal 
echocardiography was not used due to esophageal varicies and the coaxial alignment with the ring of the
deteriorated bioprosthesis was guided only by fluoroscopy. Before the introduction of the prosthesis the 
guidewire was accidentally dislocated towards the aortic valve and the 29-mm Edwards SAPIEN III balloon 
expandable bioprosthesis (Edwards Lifesciences, Irvine, CA) was wrongly released, through a 21F sheath, in 
ascending aorta with following migration in aortic arch (figure 1A).  














immediately implanted in the degenerated bioprosthesis using the same approach under fluoroscopy and 
echocardiography guidance, during rapid ventricular pacing (figure 1B). Fortunately the position of the 
dislocated mitral prosthesis, perfectly aligned in the arch, did not interfere with the catheters passage. 
Considering this, the dislocated prosthesis was then successfully stabilized in the aortic arch introducing 
through the right femoral artery a bare aortic stent  (E-xl 36-32, JOTEC), allowing also an adequate 
perfusion of epiaortic vessels (figure 1C). The patient was extubated 14 hours after the procedure, no 
complications occurred, the post-opeartive chest X-ray showed the right positioning of the prosthesis (figure 
2A) and he was discharged from hospital 8 days after valve implantation with warfarin therapy.  The pre-
discharge echocardiogram showed no mitral regurgitation nd any paravalvular leakage, mitral valve area 
was 2.8 cm2 with a mean gradient of 7 mmHg, LV ejection fraction was 43% (figure 2B, 2C). 
 
Comment 
The first cases of transcatheter aortic valve in valve implantation, performed in high-risk patient for
degenerated aortic bioprosthesis, have been describd in 2006 [2] and Cheung reported the first case of 
transapical transcatheter mitral valve in valve implantation in 2009 [3]. The development of the transcatheter 
heart valve procedures allowed the treatment of degen rated bioprostheses to become an elegant and viable
alternative in high risk patients; further studies have likewise praised the transapical approach to allow direct 
and coaxial access to the mitral valve. The results pre ented by Wilbring [4] with the TA-MVI confirmed the 
feasibility and repeatability of the procedure. However, despite the excellent results, also some complications 
have been reported. Mick et al. [5] presented a case of valve in valve migration to the left atrium, they 
planned a novel approach: they planned for a catheter-based transatrial approach for a repeat valve-in-valve 
procedure via right thoracotomy. One case of late dislo gment, 17 month later, was also reported by Zegdi t 
al. [6]; to solve the problem a mitral and aortic valve replacement was performed with 2 mechanical bileaflet 
prostheses. From what we know an unusual complication like this that we reported is not yet present in the 
literature. The dislocation and consequent migration of the SAPIEN III prosthesis in aortic arch is a 
catastrophic situation that opens the doors at two different possible scenarios: a re-sternotomy with deep or 














patients, or trying to resolve the problem with a trans-catheter solution. Our choice was motivated by two 
important aspects: first, the mitral prosthesis presented a 29mm caliber, enough to be expanded against the 
aortic wall, secondly the alignment of the dislocated mitral valve in the aortic arch allow the passage of the 
catheters trough the valve. Taking this into account we used a bare aortic stent to fix the valve but also to 
allow an adequate brachiocephalic trunk and left carotid artery perfusion. This approach provided an 
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Figure 1. Fluoroscopic image showing (A) the wrong release of 29-mm Edwards SAPIEN prosthesis. (B) the 
dislocation in arch of 29-mm Edwards SAPIEN prostheis and the other 29-mm Edwards SAPIEN in mitral 
position inside the degenerated prosthesis. (C) the bar  aortic stent graft  (E-xl Aortic stent JOTEC) 
stabilizing 29-mm Edwards SAPIEN, dislocated in arch. 
Figure 2. (A) Post-operative fluoroscopic image showing the right positioning of the prosthesis (B) Three-
dimensional transthoracic echocardiography and (C) Bi-dimensional transthoracic echocardiography 
showing the 29-mm Edwards SAPIEN prosthesis (Edwards Lifesciences LLC, Irvine, CA) successfully 
placed inside the degenerated 31-mm Hancock bioprosthesi . 
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